Last update Feb. 14, 2024

C15H20Cl2N2O3

Compatible

Safe product and/or breastfeeding is the best option.

Raclopride is a typical antipsychotic related to sulpiride, selective dopaminergic D2 receptor antagonist. Labeled with radioisotopes such as Carbon-11 (Raclopride-11C) it is used in the non-invasive study of degenerative brain diseases by positron emission tomography (PET).

It is excreted in breast milk in small concentrations, much lower than those detected in plasma. (Moses 2005)

The short radioactive half-life of 11C (20.4 minutes) means that no breastfeeding interruption time is required, as noted by international bodies and expert authors. (ACMUI 2019 table 4 p21, IAEA 2018 p283, ICRP 2015 table D1 p320-21, Moses 2005).


See below the information of this related product:

Alternatives

We do not have alternatives for C15H20Cl2N2O3 since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

C15H20Cl2N2O3 is Raclopride 11C in Molecular formula.

Is written in other languages:

C15H20Cl2N2O3 is also known as

Group

C15H20Cl2N2O3 belongs to this group or family:

Pharmacokinetics

Variable Value Unit
Molecular weight 347 daltons
T½ 0.34 hours
M/P ratio 0.12 -

References

  1. ACMUI: Advisory Committee on Medical Uses of Isotopes. Sub-Committee on Nursing Mother Guidelines for the Medical Administration of Radioactive Materials. Final Report Submitted: January 31, 2019 Full text (link to original source)
  2. IAEA - International Atomic Energy Agency. Radiation Protection and Safety in Medical Uses of Ionizing Radiation IAEA Safety Standards Series No. SSG-46, 2018 Abstract Full text (link to original source)
  3. ICRP 2015: Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, Stabin M, Taylor D, Bolch W, Carlsson S, Eckerman K, Giussani A, Söderberg L, Valind S; ICRP.. Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. ANNEX D. RECOMMENDATIONS ON BREAST-FEEDING INTERRUPTIONS. p 320-21. ICRP Publication 128. Ann. ICRP 44(2S). 2015. Table D1 p320-21. Abstract Full text (link to original source)
  4. Moses-Kolko EL, Meltzer CC, Helsel JC, Sheetz M, Mathis C, Ruszkiewicz J, Bogen D, Confer AL, Wisner KL. No interruption of lactation is needed after (11)C-WAY 100635 or (11)C-raclopride PET. J Nucl Med. 2005 Abstract Full text (in our servers)

Total visits

309

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM